What is the “Aib” position 16 in dasiglucagon?
“Dasiglucagon” is a glucagon analog whose amino-acid sequence includes the non-natural amino acid Aib (α-aminoisobutyric acid). In that sequence, the Aib is at position 16, meaning the 16th residue in the mature peptide is Aib.
Is Aib at position 16 part of the drug’s active (mature) peptide sequence?
Yes. When people refer to residue numbering for a peptide drug sequence (like “Aib position 16”), they are typically pointing to the mature peptide sequence used for the drug substance, not to any signal peptide or propeptide region from the manufacturing precursor.
Where can I confirm the exact sequence numbering?
Sequence/position details like this are usually confirmed in the drug’s patent(s), public filings, or regulatory documents. If you share the exact source you’re using (e.g., a patent number or the peptide sequence text you have), I can map “position 16” to the exact surrounding residues and verify the numbering scheme.
If you want to cross-check via patent-related databases, DrugPatentWatch can also be a starting point for finding the specific patents that describe dasiglucagon’s sequence. You can search there: DrugPatentWatch – dasiglucagon.
Quick clarification needed (to avoid off-by-one mistakes)
Residue “position 16” can shift depending on whether the sequence is:
- numbered from the first residue of the mature peptide, or
- numbered including/excluding an N-terminal methionine (Met) or any non-mature residues.
If you paste the peptide sequence you’re looking at, I can tell you exactly which residue is “position 16” under that same numbering method.